IVF products approved in Russia

IVF products approved in Russia

Vitrolife has obtained approval for its IVF nutrient solutions in Russia.
Approval comprises 35 products.  


“Russia is one of the markets that we have decided to focus on. Penetration for
IVF is relatively low today, but it is assessed that this market can grow faster
than average during the coming years” says Nils Sellbom, Director of Sales at
Vitrolife.

14,000 infertility treatments are today carried out each year in Russia and the
number of fertility clinics amounts to approximately 50. The potential market
value for nutrient solutions and instruments for IVF thereby amounts to
approximately SEK 30 million today. 




April 10, 2008
Kungsbacka, Sweden 

Magnus Nilsson
CEO








Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share
is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.